drugset / Trial / NCT01133366

A Study to Determine the Effects of Multiple Doses of Mipomersen (200 mg SC) on the Pharmacodynamics and Pharmacokinetics of Single-dose Warfarin

NCT01133366

Non-randomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to assess how blood clotting and thinning time is effected when a single dose of warfarin is given alone and when a single dose of warfarin is given with mipomersen; to assess the blood levels of a single dose of warfarin, a single dose of mipomersen, and a single dose of warfarin when given with mipomersen; and to assess the safety of mipomersen when given with or without warfarin.

Timeline

Start
2010-05
Primary completion
2010-05
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Warfarin Small molecule 25 mg Oral
Subject mipomersen Antisense oligonucleotide 200 mg Subcutaneous

Indications

No indication recorded.